Evidence map›Paper›PMID 42504064›Full record

Trial reportDiabetes, obesity & metabolism2026

Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).

Helena W Rodbard, Concetta Irace, Jevitha Lobo, Konstantinos Makrilakis, Prachi Priyadarshini, Suvanjaa Sivalingam, Santiago Tofé Povedano, Anuj Bhargava

Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Helena W RodbardEndocrine and Metabolic Consultants, Rockville, Maryland, USA.ORCID 0000-0002-6187-8445
Concetta IraceUniversity Magna Graecia, Catanzaro, Italy.ORCID 0000-0001-5182-5473
Jevitha LoboNovo Nordisk India Pvt Ltd, Bengaluru, India.
Konstantinos MakrilakisLaiko General Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.ORCID 0000-0002-4160-0577
Prachi PriyadarshiniNovo Nordisk India Pvt Ltd, Bengaluru, India.
Suvanjaa SivalingamNovo Nordisk A/S, Søborg, Denmark.
Santiago Tofé PovedanoUniversity Hospital Son Espases, Palma de Mallorca, Spain.ORCID 0000-0003-3034-4667
Anuj BhargavaIowa Diabetes Research, West Des Moines, Iowa, USA.

Funding

Novo Nordisk
6 · The paper itself

Abstract

aimsType 2 diabetes (T2D) management with basal insulin can lead to hypoglycaemia and weight gain. SUSTAIN OPTIMIZE compared once-weekly semaglutide 2.0 mg as add-on to dose-reduced insulin glargine (Sema+IGlar MATERIALS AND

methodsSUSTAIN OPTIMIZE was a 40-week, phase 3b, open-label, randomised study. Adults with T2D, overweight (body mass index ≥ 25 kg/m

resultsOverall, 573 participants were randomised. Sema+IGlar

conclusionsOnce-weekly subcutaneous semaglutide 2.0 mg as add-on to dose-reduced IGlar achieved superior reductions in HbA

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsInsulin GlargineOverweightSemaglutideAdultAgedBlood GlucoseDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleGlycated HemoglobinHumansHypoglycemiaBlood GlucoseGlucagon-Like PeptidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulin GlargineSemaglutideclinical trialGLP‐1glycaemic controlhypoglycaemiainsulin glarginesemaglutide

Identifiers

PMID42504064
PMCPMC13538791

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.